APR 11 TOTAL SE		
FORM PTO-1449	SERIAL NO.	CASE NO.
Et a mouldit	09/902,572	10466/77
LIST OF PATENTS AND PUBLICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE	July 10, 2001	1642
STATEMENT		
(use several sheets if necessary)	APPLICANT(S): Ashkenazi et al	

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
			750	-11/51
			HEU	SIVED
			APR	2 2002
				, , , , , , , , , , , , , , , , , , , ,

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS				150110=		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSI YES	ATION NO
		ļ				·
	<del> </del>	1				

EXAMINER INITIAL		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
AND	A1	Blast Results A1-A21, GenBank
AND	A2	Blast Results, B1-B6, Dayhoff
	L	

·			
EXAMINER /	/	DATE CONSIDERED	
Swedd & hel	1-6.	11/11/03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Rev. Dcc.-99



SHEET 5 of 5

SHEET 5 OF			JILLI J OI J
INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.	SERIAL NO.
		39780-1618P2C40	09/902,572
		APPLICANT Ashkenazi et al.	
		FILING DATE: 07/10/01	GROUP: 1636
	OTHER DOCUMENTS	Including Author, Title, Date, Pertin	ent Pages, Etc.)
AA2	Collins, et al; "Characterization factor in vivo", Br. J. Pharmac	on of the increase in vascular permeabilicol. (1993), 109, 195-199.	ty induced by vascular permeability
AD2-		ue fluorimetry for determination of puli fluid resuscitation of burn shock", Burn	
Apol.		lial growth factor (VEGF)-like protein f Acad. Sci., USA, Vol. 96, pp. 3071-307	
j			RECEIVE
			JUN 0 2 2003
			Trail 2 2003
<u> </u>			TECH CENTER 1600/2900
			-1000/2900
	<u> </u>	· · · · · · · · · · · · · · · · · · ·	
		· <del>····································</del>	
EXAMINER &	wealth helf	DATE CONSIDERED ///i	/03
	· • // =		



SERIAL NO. ATTY. DOCKET NO. INFORMATION DISCLOSURE FECEVEL VEL **STATEMENT** 39780-1618P2C40 09/902,572 APPLICANT Ashkenazi et al. PTO-1449 GROUP: 167 FILING DATE: 07/10/01 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Cho et al; "Cloring of novel serine carboxypeptidase precursor" Direct submission to Microbiolo Hee University, Hoeki 1, Seoul, Korea; RISC HUMAN, Submitted 26 June, 2000. Komatsoulis et al; "Isolated nucleic acid-molecules encoding a human secreted protein is used in preventing, treating or ameliorating a medical condition," P\_AAU96225; WO200224721-A1; Filing: 9 Jan, 2001; Publication date: 28 March 2002. Shimkets et al; "Novel nucleic acids and peptides derived from open reading frame X, useful for treating e.g. cancers, proliferative disorders, neurodegenerative disorders and cardiovascular disease," P\_AAB41675, WO200058473-A2, Filing: 31 March 1999; Publication date: 05 October 2000. Liu et al; Direct submission to Molecular Medical Center for Cardiovascular Disease, Cardiovascular Institute, CAMS AND PUMC; 167, Bei Li Shi Lu, Beijing 160037, P.R. China, AAG39285.1; Accession No: AFT13214; submitted 15 December 1998. Chen et al; "Clouing of a novel retinoid-indusible serine carboxypertidase from vascular smooth muscle cells," J. Biol. Chem. 276 (36), 34175-34181 (2004); NP 067639. Baker et al; "One hundred and eighty seven nucleic acids encoding RRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammall, P ABB84842; WO200200690-A2, Pat 19 Jul, 2002, Filing: July 9, 2001; Publication Date: Japuary 3, 2002. Baker et al: "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal, P\_ABB95448; WO200208284-A2, Pat 19 Jul, 2002, Filing: July 9, 2001; Publication Date: January 31, 2002. White et al; "Identifying a gene involved in disease for treating hypoxia-regulated conditions, comprises comparing the transcriptome/ proteome of two cell types under different conditions and identifying a differentially regulated gene" P\_ABP65102; WO200246465-A2; Rublication Date: 13 June 2002; Pat 12 Nov, 2002. Miano et al; "New retinoid-inducible serine carboxypeptidase proteins and nucleic acids, useful for detecting or treating vascular diseases, e.g. vascular hyperplasia, atherosclerosis, asthma, glomerulonephritis, hypertension" P ABB99213; WO200268599-A2, Publication date: 06 September 2002 Pat 29 Nov, 2002. Ashkenazi et al; "Sixty one nulcic acids encoding PRO polypeptides which are useful in the treatment of skin diseases, cancers and neurodegenerative diseases", P\_AAB80255; WO200104311-A1 Pat 24 Apr, 2001, Filed: February 22, 2000, Publication date: 18 January 2001. **EXAMINER** DATE CONSIDERED



SHEET 1 OF 5

		SHEET LOF 5	
INFORMATION DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.	
STATEMENT	39780-1618P2C40	09/902,572	
PTO-1449	PTO-1449 APPLICANT Ashkenazi et al.		
	FILING DATE: 07/10/01	GROUP: 1736, 0 2 2003	
OTHER DOCUMENTS (	Including Author, Title, Date, Pertine	ent Pages, Etc.)	
promoting or inhibiting angiog	prising a PRO230, PRO216 or PRO302 genesis and/or cardiovascularisation in r y, <del>2001, filed:</del> November 29, 1999		
useful for promotion or inhibit	mprising PRO <del>230</del> , PRO216 or PRO302 ion of cardiovascularisation, angiogene 2-A2, Pat 20 July 2000, filed: Septembe	sis or endothelialisation in mammals",	
	nan genes and polypeptides used in, e.g 09914328-A2, Pat 25 June 1998, filed:		
	prising human polypoptides with anti-ar 19 <del>99, filed: Sopte</del> mber 14, 1998.	ngrogenic activity", P_AAX25445;	
Ashkenazi et al; "Sixty one nu skin diseases, cancers and neur 2001, Filed: Feb. 22, 2000.	leic acids encoding PRO polypeptides vodegenerative diseases", P_AAF72416	which are useful in the treatment of ; WQ200104311-A1, Pat 24 April	
	eighty seven nucleic acids encoding PF r, endothelial or angiogenic disorders in y 2002, Filing: July 9, 2001.		
	eighty seven mucleic acids encoding PF r, endothelial or angiogenic disorders in y 2002, Filing: June 20, 2001.		
	Fong et al; "Promotion of inhibition of angiogenesis and cardiovascularization," AX098272; WO0119987-A11, Pat 2 Apr. 2001, Pub: Mar. 22, 2001.		
Baker et al; "Composition and angiogenesis" AX454466; WC	Baker et al; "Composition and methods for the diagnosis and treatment of disorders involving angiogenesis" AX454466; WO0208284-A 51; Pat 6 July 2002, Pub: Jan 31, 2002.		
Wood et al; "Secretory and tran JP2001516580-A 210; Pat 27 A	Wood et al; "Secretory and transmembrane polypeptide and nucleic acid encoding the same" BD075577; JP2001516580-A 210; Pat 27 Aug. 2002, Oct 2, 2001.		
Wood et al; "Secretory and tran JP2002238588-A 210, Pat 18 I	Wood et al; "Secretory and transmembrane polypoptide and nucleic acid encoding the same" BD173394; JP2002238588-A 210, Pat 18 Feb. 2003.		
Wood et al, "Sescetory and tran JP2002238587-A 210; Pat 18 f	Wood et al. "Sestetory and transmembrane polypeptide and nucleic acid encoding the same" BD173075; JP2002238587-A 210; Pat 18 Feb. 2003.		
Baker et al; "Composition and angiogenesis" AX490944; WO	methods for the diagnosis and treatmer 0200690-A51; Pat 16 Aug. 2002.	nt of disorders involving	
Wood et al; "Secretory and transmembrane polypeptide and nucleic acid encoding the same" BD172756; JP2002238586-A 210; Par 18 Feb. 2003.			
EXAMINER Second to hel	DATE CONSIDERED 11/17/	43	



(Ex		SHEET 2 OF 5	
INFORMATION DISCLOSURE	ATTY. DOCKET NO.	SERIAL NO.	
STATEMENT	39780-1618P2C40	09/902,572	
PTO-1449	APPLICANT Ashkenazi et al.		
	FILING DATE: 07/10/01	GROUP: 1636 JUN	
OTHER DOCUMENTS	(Including Author, Title, Date, Pertin	ent Pages, Etc.)	
Wood et al; "Secretory and tr IP2092723786-A 210; Par 18	ansmembrane polypeptide and nusleic as Feb, 2003.	SERIAL NO.  09/902,572  GROUP: 1636  June Pages, Etc.)  acid encoding the same BD175428;	
Wood et al; "Secretory and tr JP2002253280-A 210; Pai 18	ansmembrane polypeptide and nucleic as Mar, 2003.	acid encoding the same" BD175428;	
detecting or treating vascular	ducible serine carboxypeptidase protein diseases, e.g. vascular hyperplasia, atte sion" P_ABV72656; WO200268599-A	rosclerosis, asthma	
comparing the transcriptome/	ne involved in disease for treating hypo proteome of two cell-types under differ P_ABV77921; WO200246465-A2, Pat	ent conditions and identifying a	
Cho et al; "Cloning of novel Kyung Hee University, Hoek	serine carbox/peptidase precursor" Dir i 1, Seoul, Korea; AF282618; Submitte	ect submission to Microbiology, d 26 June, 2000, Priority 27 Sep, 2000	
Chen et al; "Cloning of a nov cells" NM 021626; J. Biol. C	chetinoid-inducible serine sarboxypept them. 276 (36), 34175-181 (2001).	idase from vascular smooth muscle	
the specification, and for the	thesizing polynucleotides, particularly the detection and/or diagnosis of the abnormal ST49: EP1074617-A2, Pat 26 June, 20	nality of the proteins encoded by the	
correlating with presence of p	d nucleic acid molecule associated with prestate cancer, useful for detecting pres 21; WO200160860-A2; Pat 16 Sep, 200	ence of prestate cancer, stage of	
Isogai et al; Direct submissies Chiba 292-0812, Japan; AKO	n to Helix Research Institute, Genomics 27373; submitted 10 May, 2001.	Laboratory, 1532-3 Yana, Kisarazu,	
Ota et al; "Primer for synthesi Pat 17 Jan, 2003.	zing full-length cDNA and use thereof	, BD157571; JP 2002191363-A12414	
Schlegel et al; "New isolated detecting compounds for treat	Schlegel et al; "New isolated nucleic acid for diagnosing and treating cervical cancer and for assessing and detecting compounds for treating the cancer"; P_AAH72787; WO200142467-A2; Pat 19 Sep, 2001.		
	sitions, kits, and methods for identifical XX188369; WO0142467-A 4064; Pat 6		
	with hydrophobic domains and the nucle ating e.g. cancer, Alzheimer's and inflar p, 2001.		
Kato et al; "Human proteins h WO0149728-A85; Pat 15 Aug	aving hydrophobic domains and DNAs	encoding these proteins"; AX191563;	
EXAMINER Quality with	DATE CONSIDERED 11/17	103	



SHEET 3 OF 5

	TO ADEMARK	·	SHEET 3 OF 5
OTHER DOCUMENTS ( Liu et al; Direct submission to Institute, 167, Bei Li Shi Lu, B Shimkets et al; "Novel nucleic		ATTY. DOCKET NO.	SERIAL NO.
		39780-1018P2C40	09/902,572
1	PTO-1449	APPLICANT Ashkenazi et al.	"CA
		FILING DATE: 07/10/01	GROUP: 1696
	OTHER DOCUMENTS	Including Author, Title, Date, Pertine	ent Pages, Etc.)
	Liu et al; Direct submission to Institute, 167, Bei Li Shi Lu, F	o Molecular Medical Center for Cardiov Beijing 100037, P.R. China; AF113214;	submitted 5 Dec, 1998.
	Shimkets et al; "Novel nucleic e.g. cancers, proliferative diso P_AAC75884; WO200058473	rders, neurodegenerative disorders and	eading frame X useful for treating cardiovascular disease,
	family, useful in identifying ag	electides encoding protease homologs of gonists and antagonists for diagnosis and 6331427-B1, Pat 23 Apr, 2002.	
		w-expressed polynucleotides and polypers," P AAH89926; WO200153453-A2	
	Kato et al; "Human proteins having hydrophobic domains and DNAs encoding these proteins," AX191553; W00149728-A75; Pat 15 Aug, 2001.		
	Fong et al; "Composition comprising a PRO230, PRO216 or PRO302 polypeptide, agonist or antagonist for promoting or inhibiting angiogenesis and/or cardiovascularisation in mammals", P_AAB20341; WO200119987-A1, Pat 29 May, 2001, filed: November 29, 1999; Publication date: 22 March 2001.		
	the specification, and for the d	hesizing polynucleotides, particularly the etection and/or diagnosis of the abnorm 913; EP1074617-A2; Par 26 June, 200	ality of the proteins encoded by the
	Kato et al, "Human proteins with hydrophobic domains and the nucleic acids encoding them, useful for preventing diagnosing and treating e.g. cancer, Alzheimer's and inflammation"; P_AAE06595; WØ200149728-A2; Pat 25 Sep, 2001; Publication date: 12 July 2001.		
$\wedge$	Fong et al; "Composition comprising a PRO230, PRO216 or PRO302 polypepydes, agonists or antagonists useful for promotion or inhibition of cordiovascularisation angiogenesis or endothelialisation in mammals", P_AAY88378; WO200015792-A2, filed September 13, 1999; Publication date: 23 March 2000.		
	Chen, et al; "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration", P_AAX13387; WO9914328-A2, Pat 25 Jun, 1999, filed: September 16, 1998; Publication date: 25 March 1999.		
	Fong et al; "Composition containing human polypeptides with anti-angiogenic activity", R AAY05768; WO9914234-A2; filed: September 14, 1998; Publication date: 25 March 1999.		
·	Kato et al; unmarned protein product; CAC51169.1; WO0149728-A85; 12 Jul, 2001; Publication date:		
	Cho et al; Direct submission to AAG16692:1; Submitted 26 Ju	Microbiology, Kyung Hee University, ane, 2000.	Hoekid, Seoul, Korca;
	Isogai et al; Direct submission Chiba 292-0812, Japan; BAB5	to Helix Research Institute Genomics I 5069.1; submitted 10 May, 2001.	aboratory, 1532-3 Yana, Kisarazu,
EXAMINER	Swald & helpland	DATE CONSIDERED 11/17/18	w3